Thymic Regulatory T Cell Isolation for High-Yield Immune Tolerance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for obtaining regulatory T cells (Tregs) from peripheral blood are limited by low yield, poor quality, and inefficiency, which hampers their effectiveness in inducing immune tolerance and preventing transplant rejection and autoimmune diseases.
Innovation Solution
A method for obtaining Tregs from thymic tissue using a CD8+-non-depleted protocol with a colloidal polymer nanomatrix conjugated with CD3 and CD28 agonists, enabling high-purity and high-yield production of CD4+CD8+ Foxp3+ Tregs, maintaining their suppressive capacity and viability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If Tregs are obtained from peripheral blood using current methods, then the process is simple and quick, but the yield is low and the quality is poor
Solution Approach 1:
The patent applies preliminary action by performing CD8+ cell depletion before Treg isolation and expansion. This preparatory step removes suppressive CD8+ cells that would otherwise interfere with Treg proliferation and function, thereby improving both the yield and quality of obtained Tregs while maintaining protocol feasibility
Solution Approach 2:
The patent uses anti-CD3 and anti-CD28 coated beads as intermediary agents to stimulate and expand Tregs in vitro. These beads serve as artificial antigen-presenting structures that provide sustained T cell activation signals without requiring complex cellular interactions, thereby achieving high-yield Treg expansion with simplified protocols
2Reliability
If immunosuppressive drugs are used to prevent transplant rejection, then rejection rates decrease, but chronic toxicity and immune system damage occur
Solution Approach 1:
The patent extracts and isolates the specific suppressive function from non-specific immunosuppression by obtaining purified regulatory T cells that selectively modulate immune responses. These Tregs provide targeted immunosuppression against graft antigens while preserving the patient's overall immune competence, thereby preventing rejection without the chronic toxicity associated with broad-spectrum immunosuppressive drugs
Solution Approach 2:
The patent changes the parameter of immune suppression from pharmacological (drugs) to cellular (Tregs). By transferring living regulatory T cells that can dynamically adapt and regulate immune responses, the therapy achieves sustained rejection prevention with reduced long-term toxicity compared to static drug-based immunosuppression
3Quantity of substance
If Tregs are expanded ex vivo to sufficient numbers for therapy, then therapeutic dosage is achieved, but the quality and suppressive capacity of cells deteriorate
Solution Approach 1:
The patent performs preliminary CD8+ cell depletion before Treg expansion to remove cells that would compete for growth factors and space. This preparatory step creates optimal conditions for Treg proliferation while maintaining their phenotypic stability and suppressive function throughout the expansion process
Solution Approach 2:
The patent uses anti-CD3 and anti-CD28 coated beads that provide continuous stimulation signals to Tregs during expansion. This sustained activation maintains Treg proliferation and functional stability simultaneously, avoiding the loss of suppressive capacity that occurs with intermittent or excessive stimulation protocols
4Manufacturing precision
If CD8+ cells are depleted before Treg isolation, then Treg purity is improved, but CD4+CD8+ Foxp3+ Tregs are lost
Solution Approach 1:
The patent performs CD8+ cell depletion as a preliminary step before Treg isolation and expansion. This timing is critical because it removes suppressive CD8+ cells that would interfere with Treg function while the thymic tissue still contains abundant CD4+CD8+ double-positive Treg precursors that can be subsequently isolated and expanded
Solution Approach 2:
The patent changes the state of Treg cells from double-positive (CD4+CD8+) in thymic tissue to predominantly CD4+ after expansion by culturing in conditions that promote CD8 downregulation. This parameter change allows recovery of the suppressive subset while achieving high purity in the final product
Data Source
AI summary
The present invention provides an in vitro method for obtaining and purifying regulatory T cells from thymic tissue (or thyTreg cells), which makes it possible to obtain more than 10 billion cells from a single thymus. These thyTregs obtained in the invention have a purity of more than 95% and very high suppressive capacity, survival and viability, in addition to being safe from a clinical viewpoint. The foregoing would not require the use of massive ex vivo cell expansion protocols. The transfer of these thyTreg cells to patients enables immune tolerance induction. Thus, said cells may be used as cell therapy to induce immune tolerance in the treatment and/or prevention of transplant rejections and in autoimmune diseases.